In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Expression of miR-23a induces leukocyte telomere shortening and is associated with poor clinical outcomes in patients with coronary artery disease

Session Poster session 1

Speaker Takahito Nasu

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : T Nasu (Morioka,JP), M Satoh (Morioka,JP), Y Takahashi (Morioka,JP), K Takahashi (Morioka,JP), S Hitomi (Morioka,JP), Y Morino (Morioka,JP), M Nakamura (Morioka,JP)

Authors:
T. Nasu1 , M. Satoh2 , Y. Takahashi1 , K. Takahashi1 , S. Hitomi1 , Y. Morino1 , M. Nakamura3 , 1Division of Cardiology, Department of Internal Medicine, Iwate Medical University - Morioka - Japan , 2IDivision of Biomedical Information Analysis, Institute for Biomedical Sciences, Iwate Medical Univer - Morioka - Japan , 3Division of Cardioangiology, Nephrology and Endocrinology, Department of Internal Medicine, Iwate Medical Univer - Morioka - Japan ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 182

Telomeric repeat binding factor 2 (TRF2) is essential for telomere maintenance. MicroRNA (miR)-23a may directly inhibit TRF2 expression, inducing telomere shortening and cellular senescence. This study aimed to determine whether miR-23a and TRF2 are expressed in patients with coronary artery disease (CAD), and whether pitavastatin might affect these levels.

This study included 104 patients with CAD and 50 controls. Patients with CAD were randomized to 12 months of treatment in either a moderate lipid lowering therapy (LLT) group (pitavastatin 1mg / day) or an aggressive LLT group (pitavastatin 4 mg / day). Circulating leukocytes were obtained from peripheral blood at baseline and after 12 months. Levels of miR-23a measured using real-time RT-PCR. Levels of TRF2 protein analyzed by flow cytometer. Relative telomere length (RTL) of lymphocyte also measured using flow FISH method.

Levels of miR-23a were higher in the CAD group than in the controls (P<0.01), whereas levels of TRF2 protein were lower in the CAD group than in the controls (P<0.01). RTL was significantly lower in the CAD group than in the control group (P<0.01). Our randomized clinical study showed that aggressive LLT markedly decreased levels of miR-23a (2.78±1.29 vs. 2.09±1.17, P<0.01) and increased levels of TRF2 (2.67±1.36 vs. 3.16±1.46, P<0.01), whereas moderate LLT had no impact on levels of miR-23a (2.75±0.98 vs. 2.47±1.29, not significant) or TRF2 (2.79±1.34 vs. 2.82±1.29, not significant). Our functional approaches showed that transfection of miR-23a into isolated leukocytes resulted in regulation of TRF2 expression. After a mean follow-up of 339 days, cardiovascular events were associated with high miR-23a, low TRF2 or low RTL (all P<0.05). Multivariate analysis showed that levels of miR-23a (RR 5.2, 95% CI 2.0–15.5) were a strong predictor of cardiovascular events after adjustment for baseline characteristics.

In conclusion, elevated levels of miR-23a are involved in the progression of coronary atherosclerosis via downregulated TRF2, and may provide important prognostic information in patients with CAD. Additionally, aggressive LLT may prevent lymphocyte telomere erosion via downregulated miR-23a.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are